ITGAM and neoplasm: Il17a deficient (CCSPcre/K-rasG12D; Il17a−/−) conferred decreased tumor progression, angiogenesis, pro-inflammatory cytokines, and Gr1+ CD11b+ myeloid cell abundance (9).